Modulation and absorption of xenobiotics: The synergistic role of CYP450 and P-gp activities in cancer and neurodegenerative disorders

Current Drug Metabolism

Volumn 12, Issue 8, 2011, Pages 702-712

  Inglese, Carmela ^a   Perrone, Maria Grazia ^a   Berardi, Francesco ^a   Perrone, Roberto ^a   Colabufo, Nicola Antonio ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

CYP450; MC18; MC266; MC80; MDR; Neurodegenerative disorders; P gp; Rat everted gut sac assay

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450; ELACRIDAR; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MC 18; MC 266; MC 80; TRACER; UNCLASSIFIED DRUG; VERAPAMIL; XENOBIOTIC AGENT;

ARTICLE; DEGENERATIVE DISEASE; DRUG ABSORPTION; DRUG DESIGN; DRUG METABOLISM; DRUG TRANSPORT; EX VIVO STUDY; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN;

EID: 80053463828     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011798357015     Document Type: Article

References (79)

1. Colabufo, N.A.; Berardi, F.; Cantore, M.; Contino, M.; Inglese, C.;Niso, M.; Perrone, R. Perspectives of P-glycoprotein modulatingagents in oncology and neurodegenerative diseases: pharmaceutical,biological, and diagnostic potentials. J. Med. Chem., 2010,53(5), 1883-1897.
2. Zhou, S.F. Drugs behave as substrates, inhibitors and inducers ofhuman cytochrome P450 3A4. Curr. Drug. Metab., 2008, 9(4),310-322.
3. Cummins, C.L.; Jacobsen, W.; Benet, L.Z. Unmasking the dynamicinterplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol.Exp. Ther., 2002, 300(3), 1036-1045. (Pubitemid 34165010)
4. Colabufo, N.A.; Berardi, F.; Perrone, M.G.; Capparelli, E.; Cantore,M.; Inglese, C.; Perrone, R. Substrates, inhibitors and activatorsof P-glycoprotein: candidates for radiolabeling and imagingperspectives. Curr. Top. Med. Chem., 2010, 10(17), 1703-1714.
5. Gimenez-Bonafè, P.; Guillen Canovas, A.; Ambrosio, S.; Tortosa,A.; Perez-Tomas, R. In: Multidrug Resistance: Biological andPharmaceutical Advance in Antitumour Treatment; Colabufo,N.A., Ed.; Research Signpost: Kerala, India, 2008; pp. 63-99.
6. Gottesman, M.M.; Pastan, I. Biochemistry of multidrug resistancemediated multidrug transporter. Annu. Rev. Biochem., 1993, 62,385-427.
7. Aungst, B.J.; Blake, J.A.; Rogers, N.J.; Saitoh, H.; Hussain, M.A.;Ensinger, C.L.; Pruitt, J.R. Prodrugs to improve the oral bioavailabilityof a diacidic nonpeptide angiotensin II antagonist. PharmRes., 1995, 12(5), 763-767.
8. Kim, R.B.; Wandel, C.; Leake, B.; Cvetkovic, M.; Fromm, M.F.;Dempsey, P.J.; Roden, M.M.; Belas, F.; Chaudhary, A.K.; Roden,D.M.; Wood, A.J.; Wilkinson, G.R. Interrelationship between substratesand inhibitors of human CYP3A and P-glycoprotein. Pharm.Res., 1999, 16(3), 408-414. (Pubitemid 29162099)
9. Schinkel, A.H.; Mol, C.A.; Wagenaar, E.; van Deemter, L.; Smit,J.J.; Borst, P. Multidrug resistance and the role of P-glycoproteinknockout mice. Eur. J. Cancer., 1995, 31(7-8), 1295-1298.
10. Kim, R.B.; Fromm, M.F.; Wandel, C.; Leake, B.; Wood, A.J.J.;Roden, D.M.; Wilkinson, G.R. The drug transporter P-glycoproteinlimits oral absorption and brain entry of HIV-1 protease inhibitors.J. Clin. Invest., 1998, 101, 289-294. (Pubitemid 28067324)
11. Fromm, M.; Kim, R.; Stein, C.; Wilkinson, G.; Roden, D. Inhibitionof P-glycoprotein-mediated drug tansport: a unifying mechanismto explain the interaction between digoxin and quinidine. Circulation,1999, 99, 552-557. (Pubitemid 29061872)
12. Greiner, B.; Eichelbaum, M.; Fritz, P.; Kreichgauer, H.P.; VonRichter, O.; Zundler, J.; Kroemer, H. The role of intestinal Pglycoproteinin the interaction of of digoxin and rifampin. J. Clin.Invest., 1999, 104, 147-153.
13. Hunter, J.; Jepson, M.; Tsuruo, T.; Simmons, N.L.; Hirst, B.H.Functional expression of P-glycoprotein in apical membranes ofhuman intestinal Caco-2 cells. Kinetics of vinblastine secretion andinteraction with modulators. J. Biol. Chem., 1993, 268, 14991-14997. (Pubitemid 23206648)
14. Cavet, M.E.; West, M.; Simmons, N.L. Transport and epithelialsecretion of the cardiac glycoside, digoxin, by human intestinalepithelial (Caco-2) cells. Br. J. Pharmacol., 1996, 118, 1389-1396. (Pubitemid 26248789)
15. Terao, T.; Hisanaga, E.; Sai, Y.; Tamai, I.; Tsuji, A. Active secretionof drugs from the small intestinal epithelium in rats by Pglycoproteinfunctioning as an absorption barrier. J. Pharm. Pharmacol.,1996, 48, 1083-1089. (Pubitemid 26400301)
16. Teodori, E.; Dei, S.; Martelli, C.; Scapecchi, S.; Gualtieri, F. In:Multidrug Resistance: Biological and Pharmaceutical Advance inAntitumour Treatment; Colabufo, N.A., Ed.; Research Signpost:Kerala, India, 2008; pp. 141-169.
17. http://www.ncbi.nlm.nih.gov/books/NBK45979 for [11C]MC18 andhttp://www.ncbi.nlm.nih.gov/books/NBK45980 for [11C]MC266
18. Colabufo, N.A.; Berardi, F., Cantore, M.; Perrone, M.G.; Contino,M.; Inglese, C.; Niso, M.; Perrone, R.; Azzariti, A.; Simone, G.M.;Porcelli, L.; Paradiso, A. Small P-gp modulating molecules: SARstudies on tetrahydroisoquinoline derivatives. Bioorg. Med. Chem.,2008, 16, 362-373.
19. Martin, C.; Berridge, G.; Mistry, P.; Higgins, C.; Charlton, P.; Callaghan,R. Drug binding sites on P-glycoprotein are altered by ATPbinding prior to nucleotide hydrolysis. Biochemistry, 2000, 39,11901-11906.
20. Laéan G.; Plenevaux, A.; Rubins, D.J.; Way, B.M.; Defraiteur, C.;Lemaire, C.; Aerts, J.; Luxen, A.; Cherry, S.R.; Melega, W.P. Cyclosporine,a P-glycoprotein modulator, increases [18F]MPPF uptakein rat brain and peripheral tissues: microPET and ex vivo studies.Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 2256-2266.
21. Callaghan, R.; Ford, R.C.; Kerr, I.D. The translocation mechanismof P-glycoprotein. FEBS Lett., 2006, 580, 1056-1063.
22. Hyafil, F.; Vergely, C.; Du Vignaud, P.; Grand-Perret, T. In vitroand in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamidederivative. Cancer Res., 1993, 53, 4595-4602. (Pubitemid 23304385)
23. Kim, R.B. Drugs as P-glycoprotein substrates, inhibitors, and inducers.Drug. Metab. Rev., 2002, 34(1-2), 47-54. (Pubitemid 34311087)
24. Greiner, R.; Eichelbaum, M.; Fritz, P.; Kreichgauer, H.P.; VonRichter, O.; Zundler, J. The role of intestinal P-glycoprotein in theinteraction of digoxin and rifampin. J. Clin. Investi., 1999, 104,147-153.
25. Dü rr, D.; Stieger, B.; Kullak-Ublick, G.A.; Rentsch, K.M.; Steinert,H.C.; Meier, P.J.; Fattinger, K. St John's wort induces intestinal Pglycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin.Pharmacol. Ther., 2000, 68, 598-604. (Pubitemid 32059985)
26. Lin, J.H.; Chiba, M.; Chen, I.W.; Nishime, J.A.; deLuna, F.A.;Yamazaki, M.; Lin, Y.J. Effect of dexamethasone on the intestinalfirst-pass metabolism of indinavir in rats: evidence of cytochromeP-450 3A [correction of P-450 A] and p-glycoprotein induction.Drug. Metab. Dispos., 1999, 27(10), 1187-1193. (Pubitemid 29463606)
27. Colabufo, N.A., Berardi, F.; Cantore, M.; Perrone,; M.G. Contino,M., Inglese, C., Niso, M., Perrone, R.; Azzariti, A.; Simone G.M.;Paradiso, A. 4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators.Bioorg. Med. Chem., 2008, 16, 3732-3743. (Pubitemid 351484037)
28. Kageyama, M.; Fukushima, K.; Togawa, T.; Fujimoto, K.; Taki,M.; Nishimura, A.; Ito, Y.; Sugioka, N.; Shibata, N.; Takada, K.Relationship between excretion clearance of rhodamine 123 and Pglycoprotein(Pgp) expression induced by representative Pgp inducers.Biol. Pharm. Bull., 2006, 29(4), 779-784.
29. Vogelgesang, S.; Cascorbi, I.; Schroeder, E.; Pahnke, J.; Kroemer,H.K.; Siegmund, W.; Kunert-Keil, C.; Walker, L.C.; Warzok, R.W. Deposition of Alzheimer's beta-amyloid is inversely correlatedwith P-glycoprotein expression in the brains of elderly nondementedhumans. Pharmacogenetics, 2002, 12, 535-541. (Pubitemid 35177083)
30. Kortekaas, R.; Leenders, K.L.; van Oostrom, J.C.; Vaalburg, W.;Bart, J.; Willemsen, A.T.; Hendrikse, N.H. Blood-brain barrier dysfunctionin parkinsonian midbrain in vivo. Ann Neurol., 2005, 57,176-179. (Pubitemid 40179854)
31. Rapposelli, S.; Digiacomo, M.; Balsamo, A. P-gp transporter andits role in neurodegenerative diseases. Curr. Top. Med. Chem.,2009, 9, 209-217.
32. Pérez-Tomás, R. Multidrug resistance: retrospect and prospects inanti-cancer drug treatment. Curr. Med. Chem., 2006, 13, 1859-1876.
33. Syvänen, S.; Hooker, A.; Rahman, O.; Wilking, H.; Blomquist, G.;Langström, B.; Bergström, M.; Hammarlund-Udenaes, M. Pharmacokineticsof P-glycoprotein inhibition in the rat blood-brain barrier.J. Pharm. Sci., 2008, 97, 5386-5400.
34. Luurtsema, G.; Molthoff, C.F.; Windhorst, A.D.; Smit, J.W.;Keizer, H.; Boellaard, R.; Lammertsma, A.A.; Franssen, E.J. (R)-and (S)-[11C]verapamil as PET-tracers for measuring Pglycoproteinfunction: in vitro and in vivo evaluation. Nucl. Med.Biol., 2003, 30, 747-751. (Pubitemid 37123132)
35. Ikoma, Y.; Takano, A.; Ito, H.; Kusuhara, H.; Sugiyama, Y.; Arakawa,R.; Fukumura, T.; Nakao, R.; Suzuki, K.; Suhara T. Quantitativeanalysis of 11C-verapamil transfer at the human blood-brainbarrier for evaluation of P-glycoprotein function. J. Nucl. Med.,2006, 47, 1531-1537. (Pubitemid 47544942)
36. Lewis, D.F. 57 Varieties: the human cytochromes P450. Pharmacogenomics,2004, 5(3), 305-318. (Pubitemid 38499969)
37. McKinnon, R.A.; Burgess, W.M.; Hall, P.M.; Roberts-Thomson,S.J.; Gonzalez, F.J.; McManus, M.E. Characterisation of CYP3Agene subfamily expression in human gastrointestinal tissues. Gut,1995, 36(2), 259-267.
38. Plant, N. The human cytochrome P450 sub-family: transcriptionalregulation, inter-individual variation and interaction networks. Biochim.Biophys. Acta., 2007, 1770(3), 478-488. (Pubitemid 46136752)
39. Williams, P.A.; Cosme, J.; Vinkovic, D.M.; Ward, A.; Angove,H.C.; Day, P.J.; Vonrhein, C.; Tickle, I.J.; Jhoti, H. Crystal structuresof human cytochrome P450 3A4 bound to metyrapone andprogesterone. Science, 2004, 305(5684), 683-686. (Pubitemid 39006760)
40. Thummel, K.E.; Wilkinson, G.R. In vitro and in vivo drug interactionsinvolving human CYP3A. Annu. Rev. Pharmacol. Toxicol.,1998, 38, 389-430. (Pubitemid 28231501)
41. Zhou, S.; Yung Chan, S.; Cher Goh, B.; Chan, E.; Duan, W.;Huang, M.; McLeod, H.L. Mechanism-based inhibition of cytochromeP450 3A4 by therapeutic drugs. Clin. Pharmacokinet.,2005, 44(3), 279-304. (Pubitemid 40477790)
42. Ogasawara, A.; Kume T.; Kazama E. Effect of oral ketoconazoleon intestinal firs pass effect of midazolam and fexofenadine in cynomolgusmonkeys. Drug. Met. Disp., 2007, 35, 410-418. (Pubitemid 46333904)
43. Thomas, H.; Coley, H.M. Overcoming multidrug resistance in cancer:an update on the clinical strategy of inhibiting p-glycoprotein.Cancer Control., 2003, 10(2), 159-165. (Pubitemid 36437822)
44. Rago, R.P.; Einstein, A.; Lush, R.; Beer, T.M.; Ko, Y.J.; Henner,W.D.; Bubley, G.; Merica, E.A.; Garg, V.; Ette, E.; Harding, M.V.;Dalton, V.S. Safety and efficacy of the MDR inhibitor Incel (biricodar,VX-710) in combination with mitoxantrone and prednisonein hormone-refractory prostate cancer. Cancer Chemother. Pharmacol.,2003, 51, 297-305. (Pubitemid 36629807)
45. Bates, S.; Kang, M.; Meadows, B.; Bakke, S.; Choyke, P.; Merino,M.; Goldspiel, B.; Chico, I.; Smith, T.; Chen, C.; Robey, R.; Bergan,R.; Figg, W.D. Fojo, T. A Phase I study of infusional vinblastinein combination with the P-glycoprotein antagonist PSC833 (valspodar). Cancer, 2001, 92(6), 1577-1590. (Pubitemid 32947844)
46. Wandel, C.; Kim, R.B.; Kajiji, S.; Guengerich, P.; Wilkinson, G.R.;Wood, A.J. P-glycoprotein and cytochrome P-450 3A inhibition:dissociation of inhibitory potencies. Cancer Res., 1999, 59(16),3944-3948. (Pubitemid 29393559)
47. Fischer, V.; Rodríguez-Gascón, A.; Heitz, F.; Tynes, R.; Hauck, C.;Cohen, D.; Vickers, A.E. The multidrug resistance modulator valspodar(PSC 833) is metabolized by human cytochrome P450 3A:implications for drug-drug interactions and pharmacological activityof the main metabolite. Drug. Metab. Dispos., 1998, 26, 802-811. (Pubitemid 28376441)
48. Rowinsky, E.K.; Smith, L.; Wang, Y.M.; Chaturvedi, P.; Villalona,M.; Campbell, E.; Aylesworth, C.; Eckhardt, S.G.; Hammond, L.;Kraynak, M.; Drengler, R.; Stephenson, J.Jr. Harding, M.W.; VonHoff, D.D. Phase I and pharmacokinetic study of paclitaxel incombination with biricodar, a novel agent that reverses multidrugresistance conferred by overexpression of both MDR1 and MRP. J.Clin. Oncol., 1998, 16, 2964-2976. (Pubitemid 28417416)
49. Krishna, R.; Mayer, L.D. Multidrug resistance (MDR) in cancer.Mechanisms, reversal using modulators of MDR and the role ofMDR modulators in influencing the pharmacokinetics of anticancerdrugs. Eur. J. Pharm. Sci., 2000, 11, 265-283.
50. Dantzig, A.H.; Shepard, R.L.; Law, K.L.; Tabas, L.; Pratt, S.;Gillespie, J.S.; Binkley, S.N.; Kuhfeld, M.T.; Starling, J.J.; Wrighton,S.A. Selectivity of the multidrug resistance modulator,LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.J. Pharmacol. Exp. Ther., 1999, 290, 854-862. (Pubitemid 29344586)
51. Mistry, P.; Stewart, A.J.; Dangerfield, W.; Okiji, S.; Liddle, C.;Bootle, D.; Plumb, J.A.; Templeton, D.; Charlton, P. In vitro and invivo reversal of P-glycoprotein-mediated multidrug resistance by anovel potent modulator, XR9576. Cancer Res., 2001, 61, 749-758. (Pubitemid 32128642)
52. Dantzig, A.H.; Shepard, R.L.; Cao, J.; Law, K.L.; Ehlhardt, W.J.;Baughman, T.M.; Bumol, T.F.; Starling, J.J. Reversal of Pglycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberanemodulator, LY335979. Cancer Res., 1996,56(18), 4171-4179. (Pubitemid 26305012)
53. Wacher, V.J.; Silverman, J.A.; Zhang, Y.; Benet, L.Z. Role of Pglycoproteinand cytochrome P450 3A in limiting oral absorptionof peptides and peptidomimetics. J. Pharm. Sci., 1998, 87(11),1322-1330.
54. Perloff, M.D.; von Moltke, L.L.; Greenblatt, D.J. Ritonavir anddexamethasone induce expression of CYP3A and P-glycoprotein inrats. Ritonavir and dexamethasone induce expression of CYP3Aand P-glycoprotein in rats. Xenobiotica, 2004, 34(2), 133-150. (Pubitemid 38299715)
55. Chiou, W.L.; Chung, S.M.; Wu, T.C. Potential role of Pglycoproteinin affecting hepatic metabolism of drugs. Pharm. Res.,2000, 17(8), 903-905.
56. Katragadda, S.; Budda, B.; Anand, B.S.; Mitra, A.K. Role of effluxpumps and metabolising enzymes in drug delivery. Expert. Opin.Drug Deliv., 2005, 2(4), 683-705. (Pubitemid 41038680)
57. Kivisto, K.T.; Niemi, M.; Fromm, M.F. Functional interaction ofintestinal CYP3A4 and P-glycoprotein. Fundam. Clin. Pharmacol.,2004, 18(6), 621-626. (Pubitemid 39564261)
58. Hebert, M.F.; Roberts, J.P.; Prueksaritanont, T.; Benet, L.Z.Bioavailability of cyclosporine with concomitant rifampin administrationis markedly less than predicted by hepatic enzyme induction.Clin. Pharmacol. Ther., 1992, 52, 453-455.
59. Bocci, G.; Tuccori, M.; Emmenegger, U., Liguori, V.; Falcone, A.;Kerbel, R.S.; Del Tacca, M. Cyclophosphamidemethotrexate 'metronomic'chemotherapy for the palliative treatment of metastaticbreast cancer. A comparative pharmacoeconomic evaluation. Ann.Oncol., 2005, 16, 1243-1252. (Pubitemid 41166506)
60. Zhang, J.; Tian, Q.; Zhou, S.F. Clinical Pharmacology of Cyclophosphamideand Ifosfamide. Current. Drug. Therapy, 2006, 1, 55-84.
61. Fromm, M.F. P-glycoprotein: a defense mechanism limiting oralbioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol.Ther., 2000, 38(2), 69-74. (Pubitemid 30077981)
62. Aouali, N.; Eddabra, L.; Macadrè, J.; Morjani, H. Immunosuppressorsand reversion of multidrug-resistance. Crit Rev Oncol Hematol.,2005, 56(1), 61-70.
63. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drugtransporters: the multidrug resistance-associated proteins. J. Natl.Cancer Inst., 2000, 92(16), 1295-302. (Pubitemid 30662093)
64. Norris, M.D.; De Graaf, D.; Haber, M.; Kavallaris, M.; Madafiglio,J.; Gilbert, J.; Kwan, E.; Stewart, B.W.; Mechetner, E.B.; Gudkov,A.V.; Roninson, I.B. Involvement of MDR1 P-glycoprotein in multifactorialresistance to methotrexate. Int. J. Cancer., 1996, 65(5),613-619. (Pubitemid 26092290)
65. Kannan, P.; John, C.; Zoghbi, S.S.; Halldin, C.; Gottesman, M.M.;Innis, R.B.; Hall, M.D. Imaging the function of P-glycoprotein withradiotracers: pharmacokinetics and in vivo applications. Clin.Pharmacol. Ther., 2009, 86, 368-377.
66. Polli, J.W.; Wring, S.A.; Humphreys, J.E.; Huang, L.; Morgan,J.B.; Webster, L.O.; Serabjit-Singh, C.S. Rational use of in vitro Pglycoproteinassays in drug discovery. JPET, 2001, 299, 620-628. (Pubitemid 32979675)
67. Jia, L.; Liu, X. The conduct of drug metabolism studies consideredgood practice (II): in vitro experiments. Curr. Drug Met., 2007, 8,822-829. (Pubitemid 350238912)
68. Dörner, B.; Kuntner, C.; Bankstahl, J.P.; Bankstahl, M.; Stanek, J.;Wanek, T.; Stundner, G.; Mairinger, S.; Löscher, W.; Mü ller, M.;Langer, O.; Erker, T. Synthesis and small-animal positron emissiontomography evaluation of [11C]-elacridar as a radiotracer to assessthe distribution of P-glycoprotein at the blood-brain barrier. J. Med.Chem., 2009, 52, 6073-6082.
69. Barthe, L.; Woodley, J.F.; Kenworthy, S.; Houin, G. An improvedeverted gut sac as a simple and accurate technique to measureparacellular transport across the small intestine. Eur. J. Drug. Metab.Pharmacokinet., 1998, 23(2), 313-323. (Pubitemid 28401125)
70. Yumoto, R.; Murakami, T.; Nakamoto, Y.; Hasegawa, R.; Nagai,J.; Takano, M. Transport of Rhodamine 123, a P-glycoprotein substrate,across rat intestine and Caco-2 cells monolayers in the presenceof cytochrome P-450 3A-related compounds. J. Pharmacol.Exp. Ther., 1999, 289, 149-155. (Pubitemid 29156023)
71. Hyafil, F.; Vergely, C.; Du Vignaud, P.; Grand-Perret, T. In vitroand in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamidederivative. Cancer Res., 1993, 53, 4595-4602. (Pubitemid 23304385)
72. Kroemer, H.K.; Gautier, J.C.; Beaune, P.; Henderson, C.; Wolf,C.R.; Eichelbaum, M. Identification of P450 enzymes involved inmetabolism of verapamil in humans. Naunyn-Schmiedeberg's Arch.Pharmacol., 1993, 348, 332-337. (Pubitemid 23271638)
73. Pauli-Magnus, C.; von Richter, O.; Burk, O.; Ziegler, A.; Mettang,T.; Eichelbaum, M.; Fromm, M.F. Characterization of the MajorMetabolites of Verapamil as Substrates and Inhibitors of Pglycoprotein.JPET, 2000, 293, 376-382. (Pubitemid 30244084)
74. Hebert, M.F. Contributions of hepatic and intestinal metabolismand P-glycoprotein to cyclosporine and tacrolimus oral drug delivery.Adv. Drug Deliv. Rev., 1997, 27, 201-214. (Pubitemid 27417873)
75. De Bruyne, S.; Wyffels, L.; Moerman, L.; Sambre, J.; Colabufo,N.A.; Berardi, F.; Perrone, R.; De Vos., F. Radiosynthesis and invivo evaluation of [11C]MC80 for P-glycoprotein imaging. Bioorg.Med. Chem., 2010, 18, 6489-6495.
76. Van Waarde, A.; Ramakrishnan, N.K; Rybczynska, A.A; Elsinga,P.H; Berardi, F.; de Jong, J.R.; Kwizera, C.; Perrone, R.; Cantore,M.; Sijbesma, J.W.A.; Dierckx, R.A.; Colabufo, N.A. Synthesisand preclinical evaluation of novel PET probes for P-glycoproteinfunction and expression. J. Med. Chem., 2009, 52, 4524-4532.
77. Drozdzik, M.; Bialecka, M.; Mysliwiec, K.; Honczarenko, K.;Stankiewicz, J.; Sych, Z. Polymorphism in the P-glycoprotein drugtransporter MDR1 gene: a possible link between environmental andgenetic factors in Parkinson's disease. Pharmacogenetics, 2003,13, 259-263. (Pubitemid 36583992)
78. Cirrito, J.R.; Deane, R.; Fagan, A.M.; Spinner, M.L.; Parsadanian,M.; Finn, M.B.; Jiang, H.; Prior, J.L.; Sagare, A.; Bales, K.R.; Paul,S.M.; Zlokovic, B.V.; Piwnica-Worms, D.; Holtzman, D.M. Pglycoproteindeficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin.Invest., 2005, 115(11), 3285-3290. (Pubitemid 41567593)
79. Vogelgesang, S.; Cascorbi, I.; Schroeder, E.; Pahnke, J.; Kroemer,H.K.; Siegmund, W.; Kunert-Keil, C.; Walker, L.C.; Warzok, R.W.Deposition of Alzheimer's beta-amyloid is inversely correlatedwith P-glycoprotein expression in the brains of elderly nondementedhumans. Pharmacogenetics, 2002, 12, 535-541. (Pubitemid 35177083)